Pipeline

Terapias en desarollo

Nuestros equipos de investigación y desarrollo apuntan a los mecanismos subyacentes de la enfermedad cerebral. Nos movemos juntos hacia un objetivo singular para ofrecer terapias novedosas que redefinan el estándar de atención para los pacientes y aborden las áreas de enfermedad cerebral donde vemos la mayor necesidad.
Project Area Phase 1 Phase 2 Phase 3
Brexpiprazole Agitation in dementia of the Alzheimer’s type 3

Mode of Action

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of agitation in dementia of the Alzheimer’s type.

Brexpiprazole Post-Traumatic Stress Disorder 3

Mode of Action

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of agitation in dementia of the Alzheimer’s type.

Brexpiprazole Borderline Personality Disorder 2

Mode of Action

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of agitation in dementia of the Alzheimer’s type.